Somatostatin receptors as potentialtherapeutic targets in the treatment of advanced adrenocortical cancer. a case report
Коломеyцева А. А., Делекторскайа В. В., Орел Н. Ф., Емелианова Г. С., Бохиан В. Y., Феденко А. А.
Сибирский онкологический журнал
Т. 17, Вып. 2, С. 111-117
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.21294/1814-4861-2018-17-2-111-117
Аннотация:
background. Adrenocortical cancer (ACC) is a rare malignancy of the adrenal cortex. Therapeutic options for advanced ACC are limited. It is necessary to study new and more effective drug combinations and tumor biological targets. the purpose of the study was to determine the expression of somatostatin receptor subtypes 2A and (SSTR 2A and SSTR 5) using immunohistochemical (IHC) analysis of tumor tissue samples in patients with ACC, as well as to study the feasibility of using prolonged analogues of somatostatin in the treatment of advanced ACC. material and methods. The expression of SSTR 2A and SSTR 5 was analyzed using imunohistochemistry of tumor tissue samples from 20 patients with advanced ACC. results. The negative (0) IHC status of SSTR 2A and SSTR 5 was determined in 10 patients (50 [%]). A different staining intensity of SSTR 2A and SSTR 5 expression was found in tumor cells of 10 patients (50 [%]). The low SSTR expression was associated with low membrane immunoreactivity and high
Ключевые слова:
ACC; Somatostatin analogs; Somatostatin receptors; SSTR 2a; SSTR 5
Язык текста: Русский
ISSN: 2312-3168
Коломеyцева А. А.
Делекторскайа В. В.
Орел Н. Ф.
Емелианова Г. С.
Бохиан В. Y.
Феденко А. А.
Kolomeytseva A. A.
Delektorskaya V. V.
Orel N. F.
Emelianova G. S.
Bokhian V. Y.
Fedenko A. A.
Somatostatin receptors as potentialtherapeutic targets in the treatment of advanced adrenocortical cancer. a case report
Текст визуальный непосредственный
Сибирский онкологический журнал
Томский национальный исследовательский медицинский центр РАН
Т. 17, Вып. 2 С. 111-117
2018
Статья
ACC Somatostatin analogs Somatostatin receptors SSTR 2a SSTR 5
background. Adrenocortical cancer (ACC) is a rare malignancy of the adrenal cortex. Therapeutic options for advanced ACC are limited. It is necessary to study new and more effective drug combinations and tumor biological targets. the purpose of the study was to determine the expression of somatostatin receptor subtypes 2A and (SSTR 2A and SSTR 5) using immunohistochemical (IHC) analysis of tumor tissue samples in patients with ACC, as well as to study the feasibility of using prolonged analogues of somatostatin in the treatment of advanced ACC. material and methods. The expression of SSTR 2A and SSTR 5 was analyzed using imunohistochemistry of tumor tissue samples from 20 patients with advanced ACC. results. The negative (0) IHC status of SSTR 2A and SSTR 5 was determined in 10 patients (50 [%]). A different staining intensity of SSTR 2A and SSTR 5 expression was found in tumor cells of 10 patients (50 [%]). The low SSTR expression was associated with low membrane immunoreactivity and high